Genentech

Scientists at 23andMe and Genentech have identified 17 new genetic variants associated with Parkinson’s disease, almost doubling the total number of known risk variants for the condition, which gives scientists hints at potential new targets for drugs to treat the disease.

To mark Parkinson’s Awareness Month, we’re taking a moment to look at some of the accomplishments 23andMe has made in the study of the disease in a relatively short time....

Over the last year, three promising new treatments for symptoms of Parkinson’s became available in the United States, but progress has been less hopeful on the development of drugs to...

We’re re-posting an interview that the Michael J. Fox Foundation did with our very own Paul Cannon, PhD, 23andMe’s Parkinson’s Research Community manager. April is Parkinson’s Awareness Month and this...

This week 23andMe announced a collaboration with Pfizer Inc, allowing researchers with the drug maker to leverage 23andMe’s unique platform to conduct genome-wide associations studies, surveys and clinical trial recruitment....

Last year 23andMe and Genentech launched an online study of metastatic breast cancer to learn more about what role genes might play in how a person responds to bevacizumab, also...

In any big fight it helps to have someone in your corner and when it comes to breast cancer you want someone like Elyse Spatz Caplan and the people at...

Earlier this year 23andMe and Genentech launched an online study of metastatic breast cancer to learn more about how genes might play a role in how a person responds to...

23andMe’s latest research paper, published in the journal BMC Medical Genetics, shows that genetic factors influence whether women have double As or double Ds. This might sound a bit frivolous at first but our research uncovered surprising connections between the genetics of breast size and the genetics of breast cancer.

Cancer is not one disease, but many, and this has been one of the most challenging aspects of researching cures for cancer. 23andMe is applying its unique research platform to study cancer with research communities focused on sarcoma, myeloproliferative neoplasms, and metastatic breast cancer. Patients from all over the world can contribute directly to research and connect with others who have their disease, all while learning more about themselves.